Synthaverse S.A.

WSE:SVE Stock Report

Market Cap: zł304.3m

Synthaverse Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Mieczyslaw Starkowicz

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.4yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure3.5yrs

Recent management updates

Recent updates

Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 28
Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

CEO

Mieczyslaw Starkowicz

2.4yrs

Tenure

Mr. Mieczyslaw Starkowicz serves as President of the Management Board and Chief Executive Officer at Synthaverse S.A. (formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.) since August 202...

Board Members

NamePositionTenureCompensationOwnership
Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Boardno datazł24.00k6.48%
PLN 19.7m
Konrad Miterski
Member of the Supervisory Boardno datazł42.00k0.072%
PLN 219.3k
Wiktor Napióra
Vice Chairman of the Supervisory Boardno datazł40.00k7.2%
PLN 21.9m
Dariusz Kucowicz
Member of Supervisory Board17yrszł39.00k0.31%
PLN 929.1k
Maciej Korniluk
Member of Supervisory Board2yrsno datano data
Jaroslaw Blaszczak
Chairman of the Supervisory Boardno datazł113.00k2%
PLN 6.1m
Dirk Pamperin
Member of the Supervisory Board4.9yrszł37.00kno data
Maciej Siedlar
Member of Supervisory Board2yrsno data0.14%
PLN 433.8k

3.5yrs

Average Tenure

Experienced Board: SVE's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 20:04
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution